NeuroSense Therapeutics Ltd Dossier
Qualitative Analysis
Business overview
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Herzliya, Israel. The company is dedicated to discovering and developing targeted, multi-pathway combination therapies for patients suffering from severe, debilitating neurodegenerative disorders, including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease. NeuroSense's lead drug candidate, PrimeC, is a novel, proprietary extended-release oral formulation combining two FDA-approved drugs—ciprofloxacin and celecoxib—designed to synergistically target key mechanisms of neurodegeneration such as neuroinflammation, iron accumulation, and impaired RNA regulation.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing PrimeC toward early market entry in Canada via Health Canada's Notice of Compliance with Conditions (NOC/c) pathway [2.3.4]. This includes preparing for a pre-NDS meeting and aiming for a formal submission.
Expected impact: Establishes an early commercial footprint and provides real-world data to support global expansion, targeting a peak Canadian market opportunity of $100M to $150 million.
Scaling up the production of PrimeC to commercial levels and qualifying U.S. and Canadian DMF and CEP holders for its active ingredients to secure the supply chain.
Expected impact: Ensures swift, reliable, and scalable commercial supply of PrimeC for both late-stage clinical trials and potential market launch.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Recipharm's formulation scientists successfully developed a unique, controlled-release tablet that synchronizes the release of PrimeC's active ingredients (ciprofloxacin and celecoxib) [2.3.1]. This partnership supports Phase 3 clinical trials and commercial supply, including manufacturing for early access in Canada.
Terms: Specific financial terms were not publicly disclosed.
Utilizing NeuroKaire's proprietary platform to reprogram patient blood cells into mature human cortical neurons to evaluate PrimeC's cellular effects and neuroplasticity in parallel with clinical outcomes from the Phase 2 RoAD trial.
Terms: Specific financial terms were not publicly disclosed.